Other than in patients with lung cancer where data are limited about peripheral blood immune cells as predictors of immunotherapy response [27,28], investigators repeatedly addressed this question in melanoma, an entity where ICB, especially through a pharmacological blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), is widely established. This evidence concerns the gene CTLA4 and lung cancer.